- Home
- INCY vs U Comparison
INCY vs U Comparison
Compare INCY & U Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INCY | U |
|---|---|---|
| Founded | 1991 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Retail: Computer Software & Peripheral Equipment |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0B | 19.0B |
| IPO Year | 1993 | 2020 |
Fundamental Metrics
Financial Performance| Metric | INCY | U |
|---|---|---|
| Price | $102.54 | $45.80 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 20 |
| Target Price | ★ $90.71 | $37.66 |
| AVG Volume (30 Days) | 2.0M | ★ 8.1M |
| Earning Date | 10-28-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3878.02 | N/A |
| EPS | ★ 5.90 | N/A |
| Revenue | ★ $4,813,105,000.00 | $1,803,658,000.00 |
| Revenue This Year | $19.59 | $3.13 |
| Revenue Next Year | $10.88 | $12.89 |
| P/E Ratio | $17.37 | ★ N/A |
| Revenue Growth | ★ 18.09 | N/A |
| 52 Week Low | $53.56 | $15.33 |
| 52 Week High | $109.28 | $46.94 |
Technical Indicators
Market Signals| Indicator | INCY | U |
|---|---|---|
| Relative Strength Index (RSI) | 54.83 | 65.76 |
| Support Level | $100.55 | $43.51 |
| Resistance Level | $107.61 | $45.66 |
| Average True Range (ATR) | 2.94 | 2.04 |
| MACD | -0.98 | 0.58 |
| Stochastic Oscillator | 45.19 | 90.39 |
Price Performance
Historical ComparisonAbout INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About U Unity Software Inc.
Unity Software Inc provides a software platform for creating and operating interactive, real-time 3D content. The platform can be used to create, run, and monetize interactive, real-time 2D and 3D content for mobile phones, tablets, PCs, consoles, and augmented and virtual reality devices. The business is spread across the United States, Greater China, EMEA, APAC, and other Americas, and key revenue is derived from the EMEA region. The products are used in the gaming industry, retail, automotive, architecture, engineering, and construction.